Skip to content

Q2 FY27 Earnings Results

Q2 FY27 earnings, Jul–Sep 2026: 558 Indian listed companies have reported; median profit growth is +20.8% on last year, and 72 of 146 companies with analyst estimates beat them. Quarter ended 30 Sep 2026.

Q1Q2Q3Q4
Q3 FY27 →
Declared
558/1,023
54% filed
Profit breadth
71% / 27%
grew / declined · 462 comparable
Median sales YoY
+22.6%
across all reporters
Median profit YoY
+20.8%
across all reporters
Beat / missed
72 / 58
of 146 covered
Strongest / weakest
Chemicals +50.8%
Realty −16.6%
median profit growth, 10+ reporters
LargestFastest profit growthFastest sales growthBiggest beatsBiggest misses
Clear filters 1–24 of 24
CompanyRevenue (₹ Cr)Profit (₹ Cr)Per share8Q profit
Symbol Sector Reported YoY QoQ Reported YoY EPS vs consensus Trend
DRREDDY Dr Reddys Laboratories LtdHealthcare8,698down−1.5%up+7.4%913down−31.7%—Beat +22.8% est. 9.04
CIPLA Cipla LtdHealthcare7,404down−2.4%up+4.0%852down−37.1%—Miss −6.2% est. 11.58
TORNTPHARM Torrent Pharmaceuticals LtdHealthcare4,979up+50.8%up+1.2%534down−9.6%—Miss −13.0% est. 16.15
MANKIND Mankind Pharma LtdHealthcare4,338up+17.3%up+7.6%716up+37.7%—Beat +7.9% est. 15.97
PPLPHARMA Piramal Pharma LtdHealthcare2,617up+28.0%up+15.3%5n/a—Beat +115.6% est. −0.26
ERIS ERIS Lifesciences LtdHealthcare892up+12.7%up+2.2%187up+39.7%—Beat +20.5% est. 11.00
SYNGENE Syngene International LtdHealthcare833down−8.6%up+13.1%32down−52.0%—Miss −38.9% est. 1.31
MOREPENLAB Morepen Laboratories LtdHealthcare747up+81.2%up+31.0%89up+116.8%—No estimate
AARTIPHARM Aarti Pharmalabs LtdHealthcare610up+46.0%up+13.9%71up+155.3%—No estimate
FDC FDC LtdHealthcare572up+21.0%down−14.4%49up+75.2%—No estimate
INDOCO Indoco Remedies LtdHealthcare520up+7.3%up+11.1%19n/a—Beat +134.4% est. 0.90
ACUTAAS Acutaas Chemicals LtdHealthcare437up+42.8%up+32.4%123up+71.0%—No estimate
SOLARA Solara Active Pharma Sciences LtdHealthcare417up+32.9%up+9.3%28n/a5.86No estimate
CONCORDBIO Concord Biotech LtdHealthcare309up+25.1%up+18.4%70up+10.4%—No estimate
SANOFICONR Sanofi Consumer Healthcare India LtdHealthcare263up+12.4%up+11.5%77up+21.6%—No estimate
VENUSREM Venus Remedies LtdHealthcare219up+13.3%up+22.2%26up+28.3%—No estimate
ZOTA Zota Health Care LtdHealthcare199up+54.5%up+14.6%−26n/a—No estimate
SUDEEPPHRM Sudeep Pharma LtdHealthcare197up+20.7%up+24.5%52up+10.2%—No estimate
BAJAJHCARE Bajaj Healthcare LtdHealthcare176up+18.9%up+6.0%14up+28.1%—No estimate
BETA Beta Drugs LtdHealthcare137up+33.5%up+9.1%19up+60.7%16.68No estimate
JAGSNPHARM Jagsonpal Pharmaceuticals LtdHealthcare96up+30.2%up+17.5%12down−5.5%—No estimate
FABTECH Fabtech Technologies LtdHealthcare92down−24.2%up+22.8%15down−46.5%—No estimate
SAKAR Sakar Healthcare LtdHealthcare87up+50.7%up+19.7%11up+126.1%—No estimate
NURECA Nureca LtdHealthcare59up+55.1%up+45.1%4up+11.6%—No estimate

About Q2 FY27 earnings data

When are Q2 FY27 results announced?
Q2 FY27 covers the Jul–Sep 2026 quarter. Indian listed companies have up to 45 days after a quarter closes to file their results — 60 days for the January–March quarter — so results arrive in a wave over the weeks that follow rather than all at once. A quarter that has only just ended will look sparse and fill in.
How many companies have declared Q2 FY27 results so far?
558 of 1,023 companies expected to report this quarter have filed. The rest are still to come; the count updates as filings land.
Why do some Q2 FY27 growth figures show "n/a" instead of a percentage?
Growth is left blank whenever the comparison period was not profitable. A percentage change measured from a loss is arithmetic without meaning — a swing from a ₹10 crore loss to a ₹10 crore profit is not "200% growth", and publishing it as such would flatter the company. The reported figures for both periods are still shown, so the change is there to read directly.
Does the beat/miss verdict cover every company?
No, and the denominator matters. An analyst consensus existed for 146 of the 558 companies that reported Q2 FY27 — 26.2%. Beat, missed and in-line describe only those. Every other company is marked "no estimate" rather than being counted as in line, because nobody forecast it. Revenue and profit growth, by contrast, cover every company in the table.
What counts as an in-line result rather than a beat or a miss?
Reported earnings per share within ±2% of the consensus estimate. The band is set there because a tighter one classifies rounding as news, and a wider one swallows surprises that genuinely moved a stock.
Are the figures consolidated or standalone?
Consolidated where a company reports on that basis, standalone otherwise, with all money in ₹ crore. Figures are as filed by the company with the exchanges (NSE/BSE); they are not restated or adjusted.
What does the 8-quarter trend line show?
Quarterly net profit for the last eight quarters, oldest on the left, always ending on the quarter shown in the row. Two years covers both the seasonal shape of the business and its direction. The line breaks where a quarter is missing rather than drawing across the gap, so a break is a real absence of data and not a reported collapse.
How do I find only the companies that beat estimates in Q2 FY27?
Use the Result filter above the table and choose Beat, or sort by EPS surprise to rank every covered company by how far it landed from consensus. Both are reflected in the page URL, so a filtered view can be bookmarked or shared.

Figures are as reported by companies in their quarterly filings to the exchanges (NSE/BSE), in ₹ crore. Consolidated results are shown where a company reports them, otherwise standalone. Year-on-year and quarter-on-quarter growth is omitted where the comparison period was loss-making, since a percentage change from a negative base is not meaningful. Analyst consensus is an estimate, not a forecast of outcome.